ProShare Advisors
LUMO

ProShare Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

ProShare Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,082
Closed -$45K – 1726
2018
Q3 		$45K Sell
2,082
-79
-4% -$2.4K ﹤0.01% 1730
2018
Q2 		$93K Sell
2,161
-156
-7% -$7.15K ﹤0.01% 1714
2018
Q1 		$151K Sell
2,317
-381
-14% -$27K ﹤0.01% 1592
2017
Q4 		$197K Buy
2,698
+690
+34% +$57.1K ﹤0.01% 1646
2017
Q3 		$184K Buy
2,008
+126
+7% +$9.66K ﹤0.01% 1294
2017
Q2 		$124K Sell
1,882
-122
-6% -$15.1K ﹤0.01% 1391
2017
Q1 		$435K Sell
2,004
-521
-21% -$74.4K ﹤0.01% 1060
2016
Q4 		$234K Buy
2,525
+258
+11% +$29.1K ﹤0.01% 1522
2016
Q3 		$306K Sell
2,267
-417
-16% -$41.4K ﹤0.01% 1148
2016
Q2 		$272K Buy
2,684
+28
+1% +$3.47K ﹤0.01% 1251
2016
Q1 		$435K Sell
2,656
-252
-9% -$51.1K 0.01% 1059
2015
Q4 		$952K Buy
2,908
+251
+9% +$81.7K 0.01% 756
2015
Q3 		$857K Sell
2,657
-173
-6% -$76K 0.01% 726
2015
Q2 		$1.13M Sell
2,830
-100
-3% -$42.5K 0.02% 724
2015
Q1 		$1.44M Buy
2,930
+400
+16% +$155K 0.02% 667
2014
Q4 		$905K Buy
2,530
+58
+2% +$17.3K 0.01% 910
2014
Q3 		$477K Sell
2,472
-481
-16% -$106K 0.01% 1447
2014
Q2 		$706K Sell
2,953
-1,304
-31% -$265K 0.01% 1361
2014
Q1 		$1.09M Buy
4,257
+2,864
+206% +$876K 0.01% 1235
2013
Q4 		$276K Sell
1,393
-795
-36% -$141K ﹤0.01% 1187
2013
Q3 		$370K Buy
2,188
+515
+31% +$82.9K 0.01% 1723
2013
Q2 		$297K Buy
+1,673
New +$237K 0.01% 1735

Other funds holding LUMO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProShare Advisors's LUMO Position: Q4 2018 in Review

ProShare Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2018, closing a stake of 2,082 shares — an estimated $45K sold.

ProShare Advisors first reported a position in LUMO in Q2 2013 and held it in 22 quarters. The position peaked at $1.44M in Q1 2015. 87 funds tracked by Wall St. Rank hold LUMO as of Q4 2018.

  • ProShare Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • ProShare Advisors sold 2,082 Lumos Pharma, Inc. Common Stock shares in Q4 2018, an estimated $45K.
  • ProShare Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
  • ProShare Advisors's Lumos Pharma, Inc. Common Stock position peaked at $1.44M in Q1 2015.
  • 87 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2018.

Based on ProShare Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.